Evidence map›Paper›PMID 29170141›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2018

RNA nanoparticle distribution and clearance in the eye after subconjunctival injection with and without thermosensitive hydrogels.

Zhanquan Shi, S Kevin Li, Ponwanit Charoenputtakun, Chia-Yang Liu, Daniel Jasinski, Peixuan Guo

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
  4. Nanotechnology-Based Treatment for Ophthalmic Diseases.International journal of nanomedicine · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Zhanquan ShiDivision of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.
S Kevin LiDivision of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA. Electronic address: kevin.li@uc.edu.
Ponwanit CharoenputtakunDivision of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA; Pharmaceutical Development of Green Innovations Group (PDGIG), Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand.
Chia-Yang LiuDepartment of Ophthalmology, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA; School of Optometry, Indiana University, Bloomington, IN 47405, USA.
Daniel JasinskiCollege of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry, The Ohio State University, Columbus, OH, USA; College of Medicine, Department of Physiology & Cell Biology, The Ohio State University, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA; Complehensive Cancer Center, Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University, Columbus, OH, USA.
Peixuan GuoCollege of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry, The Ohio State University, Columbus, OH, USA; College of Medicine, Department of Physiology & Cell Biology, The Ohio State University, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA; Complehensive Cancer Center, Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University, Columbus, OH, USA.
Lung Institute · USIndiana University Bloomington · USSilpakorn University · THUniversity of Cincinnati · USUniversity of Cincinnati Medical Center · US

Funding

Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatmentU01CA207946 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E., GUO, PEIXUAN · 2016 to 2020
$2.7M
RNA Nanoparticles for Ocular Drug Delivery to the Posterior EyeR21EY024409 · NEI · UNIVERSITY OF CINCINNATI · PI LI, KEVIN S. · 2015 to 2016
$441k
NCI NIH HHS U01 CA207946NEI NIH HHS R21 EY024409
6 · The paper itself

Abstract

Thermodynamically and chemically stable RNA nanoparticles derived from the three-way junction (3WJ) of the pRNA from bacteriophage phi29 DNA packaging motor were examined previously for ocular delivery. It was reported that, after subconjunctival injection, RNA nanoparticles with tri-way shape entered the corneal cells but not the retinal cells, whereas particle with four-way shape entered both corneal and retinal cells. The present study evaluated ocular delivery of RNA nanoparticles with various shapes and sizes, and assessed the effect of thermosensitive hydrogels (poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid); PLGA-PEG-PLGA) for increasing the retention of RNA nanoparticles in the eye. Fluorescence imaging of mouse eyes and fluorescence microscopy of dissected eye tissues from the conjunctiva, cornea, retina, and sclera were performed to determine the distribution and clearance of the nanoparticles in the eyes after subconjunctival injection in vivo. RNA nanoparticles entered the cells of the conjunctiva, cornea, retina, and sclera after subconjunctival delivery. The clearance of RNA pentagon was slower than both RNA square and triangle of the same designed edge length (10nm) in the eye, and the clearance of RNA squares of the longer edge lengths (10 and 20nm) was slower than RNA square of the shorter edge length (5nm), thus indicating that the size could affect ocular pharmacokinetics of the nanoparticles. At 24h after the injection, approximately 6-10% of the fluorescence signal from the larger nanoparticles in the study (RNA square of 20nm edge length and RNA pentagon of 10nm edge length) remained in the eye, and up to 70% of the retinal cells contained the nanoparticles. The results suggest that the larger nanoparticles were "gulped" in conjunctival, corneal, retinal, and scleral cells, similar to the behavior observed in macrophages. Additionally, the combination of RNA nanoparticles with the thermosensitive polymers increased the retention of the nanoparticles in the eye.

Indexed as

AnimalsEyeHydrogelsInjectionsMice, HairlessMice, Inbred C57BLNanoparticlesPolyethylene GlycolsPolyglactin 910RNAHydrogelsPolyethylene GlycolsPolyglactin 910poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid)RNADouble-stranded RNAOcular deliveryRNA nanotechnologySubconjunctivalTemperature sensitive polymer

Identifiers

PMID29170141
PMCPMC6029979
OpenAlexW2769894430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.